A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Key claim: A Phase 2 open-label dose-escalation study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in patients with polycythemia vera.
Abstract
This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Why this matters
DISC-3405 represents another investigational agent entering the PV-specific therapeutic pipeline, joining a growing roster of novel non-JAK-inhibitor approaches (sapablursen, givinostat, PRT12396) being tested in this subtype. Its appearance in a phase 2 PV-only study reinforces the trend toward subtype-tailored drug development in PV, where erythrocytosis and JAK2-driven biology offer distinct therapeutic targets compared with ET or MF. Tracking such early-phase PV-specific entrants is essential for understanding how the natural history and treatment landscape of PV may diverge further from other MPN subtypes.